More on XBIO
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.28 |
|
|||
| Open | $4.26 | ||||
| 52 Wk High | $5.20 | ||||
| 52 Wk Low | $0.21 | ||||
| Day High | $4.30 | ||||
| Day Low | $4.11 | ||||
| P/E | N/A | ||||
| EPS | $-0.01 | ||||
| Volume | 23,657 | ||||
- Form 8-K Xenetic Biosciences, For: Aug 07
- Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform
- Form 10-Q Xenetic Biosciences, For: Jun 30
- Xenetic Biosciences partner gets Israeli approval for lymphoma study
- Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination
- Xenetic Biosciences presents DNase I data at ASCO 2026 meeting
- Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival
- Form SCHEDULE 13G Xenetic Biosciences, Filed by: MJL Manager LLC
- Form SCHEDULE 13G/A Xenetic Biosciences, Filed by: RENAISSANCE TECHNOLOGIES LLC
- Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform
Entities mentioned with XBIO
- Twitter | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Earnings | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S1 | View Related Stories »
- Show More...
